Try our Advanced Search for more refined results
Life Sciences - June, 2019
333 articles
- Ex-J&J Doc Defends Co.'s Opioid Marketing In Okla. Trial
- High Court Census Ruling Could Escalate Rule Challenges
- Insurers Lose Bid To Lift Stay In J&J Talc Supplier Ch. 11
- FCA Decision Tracker: More Interpretations Of Escobar
- Chemours Sues DuPont Over 'Lowball' Cleanup Tab
- Reed Smith Atty's Widow Wants $3M Jury Verdict Restored
- Conservative Justices Cross Over To Create Unusual Lineups
- The Sharpest Dissents Of The Supreme Court Term
- Theranos Founder Holmes Gets Aug. 2020 Criminal Trial Date
- 1st Circ. Affirms Dismissal Of Investor's Biogen Suit
- Medtronic Insulin Pumps Yanked For Possible Hacking Threat
- MoFo Snags FDA Expert From Mintz As Life Sciences Partner
- Jury Awards Ky. Seed Co. $2.4M In Trade Secrets Suit
- 2nd Circ. Questions Shkreli's Bad Jury Instruction Argument
- J&J Hit With $500K Verdict In Latest Philly Mesh Case
- Sotomayor, Breyer Vie For Chattiest High Court Justice
- Top 10 Techniques For Crafting A Dazzling Brief
- Justices Told To Skip Ex-Pfizer Exec's ERISA Venue Case
- Limited Deference Owed USPTO After High Court Kisor Ruling
- 2 Firms Score $5.6M For Work On $18.7M Chiasma Deal
- The Funniest Moments Of The Supreme Court Term
- The New 'Roberts Court' Finds Its Footing
- Ex-J&J Doc Tells Okla. Judge Its Opioids Had Low Abuse Rate
- Breaking Down The Vote: High Court Term In Review
- SEC Targets 4 Attys Over Alleged Roles In PixarBio Fraud
- Goodwin-Led BridgeBio Tops 3 Biotech IPOs Totaling $749M
- The Firms That Won Big At The Supreme Court
- Senate Panel OKs Bill Targeting Tribes' Drug Patent Buys
- J&J Gets Case Removal Extension In Talc Supplier's Ch. 11
- Ancestry.com Shared Private Health Info Of Thousands: Suit
- Indian Man Charged With Drug Smuggling, Money Laundering
- Vectura Demands Another $44M In Inhaler IP Clash
- 2 Firms Steer Bracco's $450M Diagnostic Imaging Biz Buy
- Judge Asks 3rd Circ. To Probe Pa. Device Defect Claim
- Sterigenics Floats Plan To Reopen Ill. Plant And Cut Emissions
- EU Fines Canon €28M For Skirting Toshiba Deal Reporting
- A New Court Approach To DOJ And SEC Parallel Proceedings
- J&J Can't Blame Okla. For Opioid Crisis, Official Testifies
- McKesson Dodges Generic Drug Price-Fix MDL For Now
- Bayer Taps Skadden Atty To Advise On Roundup Litigation
- Medical Device Co. Gets Access To $20M In Bankruptcy Loans
- Deals Rumor Mill: Magellan, HDFC Bank, Everest Medicines
- NJ Governor Knocks Lawmakers For Dropping Opioid Fee
- Debt Collector Sued Over Medical Provider Data Breach
- Del. Justices Deny Appeal Over Unsealing Of Chemours Suit
- Key Takeaways From USDA's Biotech Regulation Proposal
- USPTO's 'Peculiar' Fee Rule Hurts Inventors, IP Attys Say
- 2nd Of 5 NY Docs Eyed For Taking Insys Kickbacks Cops Plea
- Patent Transfers Dip Nearly A Quarter, With Tech Hardest Hit
- Private Investors Inject $104M Into Encoded Therapeutics
- A Chat With Ballard Spahr Diversity Chief Virginia Essandoh
- Opioid Deaths Will Rise Without J&J Fix, Okla. Judge Told
- USPTO Launches New Round In CRISPR Patent War
- Pharma, Tech Cos. Back Proposal To Expand Patent Eligibility
- 'Superbug' Firm Gets Ch. 11 Sale OK'd, Will Sell More Assets
- Split 9th Circ. Revives Suit Over Depositor's Ponzi Claim
- Opioid MDL Judge Seems Open To Novel Deal Approach
- Stem Cell Patients Win Cert. In 'Complex And Troubling' Suit
- Colgate False Ad Class Cert. Washes Out In 9th Circ.
- Womble Bond Nabs Privacy Partner In Boston
- Big Pharma's Biggest New Cases Of 2019: Midyear Report
- Deals Rumor Mill: Magellan, Miniso, Woodford
- Enzo's DNA Testing Patents Don't Hold Up, Fed. Circ. Affirms
- Judging A Book: McMahon Reviews 'Roosevelt For The Defense'
- Vesalius Biocapital Closes €120M Life Sciences-Focused Fund
- Invisalign Maker Tries To Ditch Suit Over Expiring Patents
- Jury Orders Express Scripts To Pay $82M In Sale Fraud Suit
- 4 Firms Guide AbbVie's $63B Bet On Allergan
- Teva Pharma Gets Nod For $85M Opioid Deal With Okla. AG
- J&J Pokes At Okla.'s $13B Plan To Fix Opioid Crisis
- Mesh Case Has Weak Ties To Pa., J&J Tells State Justices
- Genetic Testing Co. Can't Limit Damages In Privacy Suit
- $925M High Enough For ViSalus Robocall Damages: Judge
- Abiomed Asks 1st Circ. Not To Revive Exec's $5M Bonus Suit
- Akorn Disclosure-Only Deals Axed Over 'Worthless' Info
- Fed. Circ. Finds Teva Infringed UCB Parkinson's Patch Patent
- 5 Cos. Heat Up July IPO Pipeline With Filings Totaling $547M
- Cancer Center Claims Drug Cos. 'Robbed' It Of IP Revenue
- 'Negotiating Class' Bid Slammed In Opioid MDL
- Fed. Circ. Lets Merck Add Parent Co. Without Resetting IPR
- High Court Roundup: Justices Won't Hear 3 Patent Cases
- DHS Contractor Fired For Reporting Boss' Fraud, Suit Says
- Drugmakers' Emails, Calls Show Price-Fix Coverup, AGs Say
- Sacklers Can't Escape NY Opioid MDL
- Valeant Kickback Case Puts Skilling To Test In 2nd Circ.
- Bristol-Myers Will Cut Top Celgene Drug To Close $74B Deal
- New FDA Database To Aid Generic-Drug Makers' Decisions
- J&J Opioid Program For Schools A Marketing Tool, Judge Told
- Ga. Court Sides With Sperm Bank In Sham-Donor Suit
- Juul May Struggle Getting FDA Approval, Gottlieb Says
- 3rd Circ. Partly Revives Heraeus Trade Secrets Suit
- What Coons And Tillis Learned At Patent Reform Hearings
- FDA Decries Drugmaker's Promos On Facebook, 'The View'
- Biggest Health And Life Sci Rulings Of 2019: Midyear Report
- Dozen Firms Guide 9 IPOs Exceeding $2B To End June
- Va. Suits Alleging Janssen Cancer Drug 'Monopoly' Sent To NJ
- Top Product Liability Cases Of 2019: Midyear Review
- Generic Drug Cos. Still Trying To Rein In AG Disclosures
- Taxation With Representation: Wachtell, Skadden, Schulte
- Anti-Terrorism Act Case Could Bring New Risks For US Cos.
- GOP Rep. Sees Patent Eligibility Reform On The Way
- Medical Device Firm Says Sabotage Suit Should Stand
- Okla.'s Abatement Plan Takes Center Stage In J&J Opioid Trial
- Whistleblower Seeks Justices' Take On $34M FCA Award Flip
- US Trustee Flags Ch. 11 Sale Restrictions In Bid For Aegerion
- 6th Circ. Rules DEA, Drug Cos. Can't Hide Opioid Data
- Deals Rumor Mill: UnitedHealth, Fortress, Chevron Phillips
- Zimmer Biomet Hit With Chancery Suit Over $2B PE Cashout
- SEC Accuses Overseas Traders Of Manipulation Scheme
- Shkreli Settles Disputes With His Former Drug Co. Retrophin
- Billionaire's Exit From Cancer Drug Co. Gets OK In Del.
- GSK Tries To Address EU Concerns Over Pfizer Merger
- 4 Biotech Cos. Raise $476M In Cooley, Davis Polk-Led IPOs
- Opko Granted Stay On Fla. 'Pump-And-Dump' Cases
- Suspects In $27M Pump-And-Dump Seek Exit From SEC Suit
- Buyers Of Cynosure Fat-Reduction Tool Push For Class Cert.
- Contaminated Cosmetics: Recalls, Lawsuits And Legislation
- J&J Exec Defends Group Okla. Witness Called 'Opioid Mafia'
- McKesson Lands Seat On Insys Creditors Committee
- Keryx Fights Investor's Bid To Lead Kidney Drug Stock Suit
- AbbVie, Investors Reach $17M Deal Over Failed Inversion
- Fed. Circ. 'Garbled' Halo Ruling, Zimmer Tells High Court
- 3rd Circ. Won't Revive Ex-Medco Exec's FCA Kickback Suit
- J&J Can't Blame Colgate, Avon In Talc Punitive Damages Trial
- San Francisco Poised To Ban Sales Of E-Cigarettes
- Clovis Directors Plead Ignorance On Rules In Drug Trial Suit
- Fenwick-Led Stoke Therapeutics Prices Upsized $142M IPO
- PTAB Says ITC Case Doesn't Bar Dental Patent Challenge
- Amphastar To Get $60M In Settlement With Rivals
- TridentUSA Ch. 11 Plan Slammed For Risking 'Repeat Failure'
- Fla. Jury Awards $70M Verdict To Couple In Asbestos Suit
- Okla. Opioid Deaths Have Familiar Face, J&J Trial Judge Hears
- Doc's Dropped Defect Defense Sank Med Mal Case, Panel Told
- Dems Question HHS Patent Enforcement, Citing Truvada Woes
- Swift Ruling Vowed On Rule Requiring Drug Prices In TV Ads
- Monsanto Looks To Whack $2B Roundup Verdict
- Judge Urged To Ax Lead Pa. Opioid Marketing Deception Case
- Debt Collection Co. Files Ch. 11 After Health Data Breach
- Was A $5M Fine Just The Cost Of Closing A $6B Deal?
- Sequenom Scores Patent Win Against Ariosa In The UK
- Deals Rumor Mill: Dish, Chi-Med, NiSource
- Asacol Buyers Say Product-Hopping Suit Requires Trial
- J&J Must Face Fast-Tracked Talc Trial On Punitive Damages
- UK Says Illumina's $1B Genomic Sequencing Deal Problematic
- Kramer Levin Lands Ex-Patterson Belknap IP Partner In NY
- A Guide To FCA Cooperation Credit For Life Sciences Cos.
- Bernstein Litowitz Seeks $11M In Fees For $45M Waste Deal
- USTR Pledges Close Work With Congress To Pass NAFTA 2.0
- The Biggest Insurance Decisions Of 2019: Midyear Report
- J&J Asks Okla. Judge To Strike 'Partisan' Opioid Expert
- Fed. Circ.'s Vimovo Ruling Harms Innovation, Horizon Says
- FCC Robocall Waiver Could Affect High-Stakes ViSalus Suit
- Allergan Hid Breast Implants' Cancer Risks, Suit Says
- In The Trade Hot Seat: What Congress May Ask Lighthizer
- Calif. Man Says Monsanto Can't Ditch $80M Roundup Award
- Mylan Escapes Novartis MS Drug Patent Suit
- Insys Hit With Nationwide Opioid Class Claim In Ch. 11
- How Purdue Opioid Win Could Bolster J&J In Okla. Trial
- Online Luxury Reseller Leads 5 IPO Launches Totaling $936M
- 5 Ways Law Firms Can Improve Their Job Interviews
- High Court Won't Review Block On ACA Birth Control Rules
- Wachtell, Skadden Shape $11.4B Pfizer-Array Deal
- Slack's Direct Listing, Robust IPO Lineup To Heat Up June
- Amazon's Arbitration Pact In 'Place Your Order' Link Holds Up
- Feds Can't Pause SEC's Civil Suit Against Ex-Theranos Exec
- 3 Takeaways As 'Negotiation Class' Idea Jolts Opioid MDL
- J&J Presses Expert On 'Opioid Mafia' Claim In Okla. Trial
- GSK Calls $90M Inhaler IP Damages 'Wildly Inflated'
- New Bill Would Reshape Drug Patent Cases In Uncertain Ways
- Patient Attys Slam 3M's Contempt Bid Over Unsealed Docs
- Insurer Fights $19M Atty Fee Bid In Heparin Coverage Suit
- Pharma Cos. Sue HHS Over Putting Drug Prices In Ads
- Troutman Sanders Lures IP Litigator From Mintz
- Chancery Keeps Alive Suit Over Repriced Anixa Stock Options
- 2 Firms Guide $825M In Health Care Data, Biopharma IPOs
- Horizon's Arthritis Drug Patent Under Scrutiny At PTAB
- Taxation With Representation: Skadden, Wachtell, Fenwick
- State Efforts To Rein In Drug Costs Have Mixed Success
- A Rare Antitrust Deferred Prosecution Agreement From DOJ
- Endo Fights Investor's Cert. Bid In Opioid Stock-Drop Suit
- Recreational Marijuana Legislation Is At A Standstill In NY
- Health Hires: Lathrop Gage, Goodwin, Shockwave Medical
- 'Negotiation Class' May Tee Up Sweeping Deal In Opioid MDL
- State Sovereign Immunity Doesn't Apply In IPRs: Fed. Circ.
- Okla. Opioid Expert Is Motivated By Money, J&J Tells Judge
- Man Charged With $4.7M Sanofi Insider Trading Scheme
- FDA Puts Forth 10-Month Deadline For E-Cig Applications
- Chamber, Drugmakers Back AbbVie In $448M FTC Fine Appeal
- 9th Circ. Breathes New Life Into CVS Drug Pricing Suit
- Ex-Theranos Execs' Bid For Docs Is Unreasonable, Feds Say
- IP Boutique Desmarais Expands To West Coast With SF Office
- J&J Loses Bid To Keep Talc Cancer Case Out Of Philly
- How To Streamline Virtual Law Team Mass Tort Defense
- Saving Seaweed Via Maine Property Law
- J&J Pushed Opioids Like Drug Dealer, Doctor Tells Trial Judge
- Feds Roasted On Proof In CEO's $3M Bank Fraud Conviction
- 4th Circ. Says Mail-Order Pharmacy Must Face Death Suit
- Medtronic Can't Escape Male Ex-Worker's Gender Bias Suit
- New Bill Would Make It Easier To Invalidate Drug Patents
- FDA Offers 'Rapid' Help As Stem Cell Approval Deadline Nears
- Shoshone Tribe Joins Opioid MDL, Details Epidemic's Impact
- Insurer Seeks Revival Of RICO Suit In Testosterone MDL
- NJ, Texas Firms Unlawfully Pocketed Mesh Funds, Suit Says
- Fed. Circ. Won't Revive Colitis Patent Axed By PTAB
- Biotech Co. Illumina Inks $14M Deal To End Stock-Drop Suit
- The SEC Is Cracking Down On Insider Trading By Lawyers
- FDA Flouted Law To Undercut $375K Drug, Suit Says
- Why I Became A Lawyer: A Fateful Phone Call
- Insuring The Ever-Growing Cannabis Industry: Part 2
- Calif. Jury Awards $12M In Talc Suit Against J&J, Colgate
- Wellness Co. CEO Pleads Guilty To Penny Stock Fraud
- Skadden, Norton Rose Guide Dassault's $5.8B Medidata Buy
- Law Firms Can Do Better With Their Mentoring Programs
- Confidentiality: The New Employee Arbitration Battleground
- J&J's Sales Plan Caused Opioid Addiction, Okla. Judge Hears
- Refined Patent Eligibility Bill Coming This Summer, Sens. Say
- U Of Minn. Says High Court Helped Case For PTAB Immunity
- PTAB Invalidates Vibrating Orthodontic Device Patent
- Wound Care Co. Pays $15M, Admits Contamination Cover-Up
- EPA Glyphosate Findings Key In Monsanto Verdict Challenges
- TridentUSA, Silver Point Seek End To Refinancing Challenge
- New HHS Inspector General 'Not Afraid To Do Anything'
- Insys Seeks Speedy Ch. 11 Sale As Liabilities Mount
- J&J Unit Seeks Kirkland's Pfizer Docs In Antitrust Fight
- Med. Device Co.'s Inflated IPO Hurt Shareholders, Suit Says
- Teva's $85M Opioid Settlement Denied Court Approval
- GSK Seeks Ax Of Zofran Birth Defect Claims
- USTR Flooded With Pleas To Resist New Tariffs On China
- BakerHostetler Lands Ex-PwC Principal To Head Int'l Tax Team
- IP's Developing Role In Cannabis Business Strategy
- Lack Of Proof Dooms Bayer Contraceptive MDL, Judge Says
- FTC Wants More Info On $4.8B Roche Buy Of Swiss Gene Co.
- Okla. Needs $295M To Undo J&J Opioid Marketing, Judge Told
- Vitamin Shoppe Sells Toxic Male Supplement, Consumer Says
- Toshiba, Canon To Pay $5M For Merger Clearance Violation
- Express Scripts Leans On BCBS Ruling In 2nd Circ. Battle
- BioScrip Investor Wants More Details On Option Care Merger
- Acadia Tries To Nix Investor Suit Over Drug Deaths
- PE-Backed Grocer Leads 5 IPO Launches Totaling $700M
- The Latest Developments In Criminal Cases Against Execs
- 'Rocket Docket' Justifies Its Name For 11th Straight Year
- The 'Newly Acquired Information' Shift In Pharma Litigation
- Thermo Fisher Drops $925M Gatan Deal Under UK Pressure
- DOJ Can't Use 'Minimal' Probe To End FCA Suit, Judge Says
- Why Bellwethers Matter In The Opioid MDL
- Merck Buys Again, Adding Biopharma Tilos In $773M Deal
- Insys Hits Ch. 11 After $225M Kickback Settlement
- Does Multidistrict Litigation Deny Plaintiffs Due Process?
- Opioid Addict Hooked From First Pill, Judge In J&J Trial Hears
- Novartis Attacks $3M Atty Fees Bid In Whistleblower Case
- Pa. County, For Now, Drops Bid To Blow Up Opioid Mass Tort
- 'Legal Impossibility' Lets Convicted Ex-NECC Execs Off Hook
- InvaGen Agrees To Admit Infringing Diabetes Drug To End Suit
- UK Litigation Roundup: Here's What You Missed In London
- Drug Cos. Hit Back In High Court 'Blocking Patent' Fight
- Meet The Top Attys In AbbVie's Antitrust Battle Royal
- Janssen OK With Combining Zytiga Suits If They're Sent To NJ
- Tribe Must Wait On USDA Rules To Grow Hemp
- J&J Talc Case Can Go Ahead In Fla. While Move To Del. Mulled
- GSK Consultants' Suit Over Prison Stint Returns To Pa. Court
- Deals Rumor Mill: Sibur, Caesars, Toro Gold
- States Call For Unredacting Of Their Generic-Drug Pricing Suit
- Fake CBD Drink Sent Co.'s Stock Skyrocketing, Suit Says
- Insys Pleads Guilty To Fraud In Opioid Bribe Scheme
- Issues To Watch In Fed. Circ. Hep C Drug Patent Case
- When Experts Are Effective In Insurance Coverage Litigation
- Combating False Celebrity Endorsements Online
- J&J Profited From Opioid Misinformation 'Virus,' Doc Says
- Chinese Co. Infringed Cholesterol Test Patents: ITC Judge
- Trade Groups Back Senate Plan To Fight Surprise Medical Bills
- AbbVie Development Partner Hits Back At $31M FTC Penalty
- Ex-Shire Unit Exec Reaches $2.5M Deal In Kickback Case
- Takeda Bid To DQ Baker Botts 'Spurious At Best,' Judge Says
- Third Rock Raises $770M To Boost Biotech Portfolio
- 3M Moves For Contempt, Says Patient Attys Used Sealed Docs
- Lilly Urges High Court To Review Its $20M Cialis Patent Loss
- J&J Asbestos Suit Sent Back To Mass. State Court
- Feds Argue Wire Fraud Needs No Insider Trading Tweaks
- Perrigo Set Up Israeli Co. To Skip Tax, US Says In $163M Row
- Measuring The Value Of A Law Firm's Social Media Efforts
- Insys Chairman To Resign In Wake Of $225M Deal With Feds
- Senate Scrutinizes Patent Bill's Effect On Drug Prices, Genes
- J&J Targets Pain Doc's Testimony In Okla. Opioid Trial
- PTAB Struggles To Parse Arguments In Acne Drug Patent Suit
- FDA, Indivior Say Braeburn Fibbing In Opioid Exclusivity Suit
- Insys To Pay $225M To End DOJ's Opioid Scheme Probe
- Mallinckrodt Used Charity As Kickback Conduit, Feds Say
- Calif. Clinic's Parent Co. Urges Toss Of Destroyed Embryo Suit
- WashU Urges 3rd Circ. To OK WARF's $32M Royalties Loss
- Calif., NY Supplement Buyers Win Cert. Of False-Ad Suit
- Court OKs Cancer Center's Revised $7.2M Antitrust Deal
- Pa. Medical Pot Cos. Can Shield Security Info From Media
- Kalobios Successor Sued Over Drug Development Deal
- Ex-Health Co. Execs Want Out Of Roche Test Strip Fraud Suit
- Pharma Co. Hid Value To Shrink Payout, Says Former Exec
- Ex-AbbVie Counsel Rejoins Ice Miller In Benefits Practice
- A Cautionary Word For Providers Of Drug Addiction Treatment
- Holland & Knight Nabs Ballard Spahr M&A Atty In Philly
- Calif. Inks Settlement With Endo Over Pay-For-Delay Scheme
- Bill To Broaden Patent Eligibility Spurs Clash At Sen. Hearing
- J&J Tells Okla. Judge It Obeyed FDA When Selling Fentanyl
- Ex-HHS Watchdog Says Anti-Fraud Revamp Going Too Slowly
- Forest Labs Scorched By 'Displeased' Judge After Fire Drill
- SG Deviated From Set Patent Law, Ariosa Warns Justices
- King & Spalding Atty Faces Sanctions Bid As Talc Trial Wraps
- Feds Win Bid To Stop Unapproved Stem Cell Treatment
- Hearing Aid Co. Workers Say Ex-Execs' Fraud Hurt Stock Plan
- Pomerantz To Lead Lexicon Pharmaceuticals Securities Suit
- Reports On USMCA Offer Industry-Specific Guidance For Cos.
- A First Look At The New Illinois Cannabis Legislation
- Illumina Hit With Derivative Suit Over $6.6B Stock Drop
- Pfizer Wins NJ High Court Review Of Forced-Arbitration Ruling
- 44 States' Generic-Drug Pricing Suit Rolled Into Pa. MDL
- What We Learned From FDA's Public Hearing On Cannabis
- Despite Amarin, ITC May Be Right Prescription For Pharma
- Drugmakers Want AGs' Generics Price-Fixing Claims Tossed
- Monsanto Looks To Nix $80M Loss In 1st Fed. Roundup Trial
- J&J Wanted To Overcome 'Opiophobia,' Okla. Judge Hears
- J&J, Colgate Created 'Severe Health Hazard,' Talc Jury Told
- Rosen Law Snags Lead Counsel In Pharma Stock-Drop Suit
- Meet The Judge Overseeing The First Opioid Trial
- PTAB Takes Up Dr. Reddy's Suboxone Patent Challenge
- Semenya Gets Nod To Compete During Testosterone Appeal
- DC, More States Sue Purdue, Sacklers Over Opioid Crisis
- Health Cos. Renew Becton Price-Fix Claim After Apple Case
- Barrett & Singal Creates New 'Research Misconduct' Practice
- Weitz & Luxenberg Urges 2nd Circ. To Toss Fraud Suit
- Hospital Must Face Suit For Using Recalled Medtronic Device
- Proposed Classes Ask To Combine Janssen Antitrust Suits
- Supreme Court Refuses 'Blocking Patent' Rule Case
- Deals Rumor Mill: Bayer, Thomas Cook, KKR
- J&J Unit Urges ITC To Investigate Intuitive Surgical's Imports
- Draft Patent Eligibility Bill Is On The Right Track